Boryung Pharmaceutical won patent nullity suit with respect to the composition of 'Gleevec'

On Apr 11, Boryung Pharmaceutical won patent nullity suit with respect to the composition of 'Gleevec' (ingredient: imatinib mesylate)'s high-dose product against Novartis, and the Supreme Court ruled in favor of Boryung. As a result, the composition patent whose duration of a patent right was till 2023 Apr, was declared invalid.

As this patent gets invalid, domestic pharmaceutical companies i...